By Natali Moss
Although this document allows the ban on medicines produced in the territory of the Russian Federation and Belarus, or made by foreign companies that carry out direct or indirect activity for the production of medicines in the territory of the aggressor or Belarus, exceptions have been made for a number of medicines. First of all, the Ukrainian market should ensure the presence of prohibited drugs.
"At the same time, the manufacturers of these analogues have a letter to confirm that they are ready to provide 100% of the country's need for a particular medicinal product. In the absence of such letters, the drug should have at least three analogues," the article reads.
In addition, the following categories of medicines cannot be prohibited: biological and immunobiological; original (innovative); for the treatment of rare (orphan) diseases; medicines, the form of release and dosage of which do not have generic substitutes in Ukraine; HIV/AIDS main medicines; Medicines for which it was concluded by February 24, 2022, the current contract for their purchase for budgetary funds.
In the event that foreign manufacturers do not want to collapse their capacities in Russia and Belarus, they run the risk of losing the Ukrainian consumer, which will mean to unite 6% of the total pharmaceutical market. But will Ukrainian pharmaceutical players benefit from this? The minimum, because the amount of problems that the industry faced during the war cannot be compensated by the removal of several drugs. "The volume of sales of monetary terms has collapsed by about a quarter.
Slovensku
Українська
English
USA
Français
Deutsch
Italiano
Polski
Čeština
Español
